1
2
Roldan Munoz, Sonia, Postmus, Douwe, de Vries, Sieta T, Arnardottir, Arna H, Dolu, İlknur, Hillege, Hans, Mol, Peter G M
Veröffentlicht in: Roldan Munoz , S , Postmus , D , de Vries , S T , Arnardottir , A H , Dolu , İ , Hillege , H & Mol , P G M 2021 , ' Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey : A Preference Study ' , Frontiers in Pharmacology , vol. 11 , 617409 . https://doi.org/10.3389/fphar.2020.617409;
2021
Veröffentlicht in: Roldan Munoz , S , Postmus , D , de Vries , S T , Arnardottir , A H , Dolu , İ , Hillege , H & Mol , P G M 2021 , ' Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey : A Preference Study ' , Frontiers in Pharmacology , vol. 11 , 617409 . https://doi.org/10.3389/fphar.2020.617409;
2021
3
Arnardottir, Arna H., Haaijer-Ruskamp, Flora M., Straus, Sabine M. J., Eichler, Hans-Georg, de Graeff, Pieter A., Mol, Peter G. M.
Veröffentlicht in: Arnardottir , A H , Haaijer-Ruskamp , F M , Straus , S M J , Eichler , H-G , de Graeff , P A & Mol , P G M 2011 , ' Additional safety risk to exceptionally approved drugs in Europe? ' , British Journal of Clinical Pharmacology , vol. 72 , no. 3 , pp. 490-499 . https://doi.org/10.1111/j.1365-2125.2011.03995.x;
2011
Veröffentlicht in: Arnardottir , A H , Haaijer-Ruskamp , F M , Straus , S M J , Eichler , H-G , de Graeff , P A & Mol , P G M 2011 , ' Additional safety risk to exceptionally approved drugs in Europe? ' , British Journal of Clinical Pharmacology , vol. 72 , no. 3 , pp. 490-499 . https://doi.org/10.1111/j.1365-2125.2011.03995.x;
2011